MYRIAD GENETICS INC (MYGN)

US62855J1043 - Common Stock

21.32  -0.08 (-0.37%)

After market: 21.32 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

MYRIAD GENETICS INC

NASDAQ:MYGN (3/28/2024, 8:26:23 PM)

After market: 21.32 0 (0%)

21.32

-0.08 (-0.37%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.92B
Shares
PEN/A
Fwd PE896.7
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MYGN Daily chart

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,600 full-time employees. The firm provides testing that helps assess an individual’s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. The company has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.

Company Info

MYRIAD GENETICS INC

322 North 2200 West

Salt Lake City UTAH 84108

P: 18015843600

CEO: R. Bryan Riggsbee

Employees: 2600

Website: https://myriad.com/

MYGN News

News Image7 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
News Image7 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...

News Image8 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
News Image8 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...

News Imagea month ago - Seeking AlphaMyriad Genetics Non-GAAP EPS of $0.04 beats by $0.03, revenue of $196.6M beats by $1.97M (NASDAQ:MYGN)

Myriad Genetics reports strong Q4 financial results, beating expectations with non-GAAP EPS of $0.04 and revenue of $196.6M (+10.6% Y/Y), raising 2024...

News Imagea month ago - Myriad Genetics, Inc.Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the

MYGN Twits

Here you can normally see the latest stock twits on MYGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example